Kiadis Pharma N.V., a biopharmaceutical company, develops NK-cell-based medicines for the treatment of life-threatening diseases in the Netherlands. Its lead product candidate is K-NK002 as an adjunctive immunotherapeutic for blood cancer patients undergoing a haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol, as well as for the treatment of liquid and solid tumors and infectious diseases; and K-NK003 that is in Phase II clinical study for the treatment of patients with acute myeloid leukemia relapse/refractory. The company is also developing K-NK-ID101, which is in Phase I/II a clinical trial for the treatment of COVID-19 infection; K-NK00X, which is in preclinical stage with K-NK-cell therapies for the treatment of hematologic and solid cancers; and K-NK004 to treat multiple myeloma. In addition, it develops NK cell therapies for a range of other cancers and infectious diseases. It has a collaboration agreement with Sanofi. The company was founded in 1997 and is based in Amsterdam, Netherlands. Kiadis Pharma N.V. operates as a subsidiary of Sanofi Foreign Participations B.V.